

RESEARCH ARTICLE

Open Access

High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts

Heidi Wähämaa^{1*}, Hanna Schierbeck¹, Hulda S Hreggvidsdottir², Karin Palmblad¹, Anne-Charlotte Aveberger¹, Ulf Andersson¹ and Helena Erlandsson Harris²

Abstract

Introduction: In addition to its direct proinflammatory activity, extracellular high mobility group box protein 1 (HMGB1) can strongly enhance the cytokine response evoked by other proinflammatory molecules, such as lipopolysaccharide (LPS), CpG-DNA and IL-1 β , through the formation of complexes. Extracellular HMGB1 is abundant in arthritic joint tissue where it is suggested to promote inflammation as intra-articular injections of HMGB1 induce synovitis in mice and HMGB1 neutralizing therapy suppresses development of experimental arthritis. The aim of this study was to determine whether HMGB1 in complex with LPS, interleukin (IL)-1 α or IL-1 β has enhancing effects on the production of proinflammatory mediators by rheumatoid arthritis synovial fibroblasts (RASf) and osteoarthritis synovial fibroblasts (OASf). Furthermore, we examined the toll-like receptor (TLR) 4 and IL-1RI requirement for the cytokine-enhancing effects of the investigated HMGB1-ligand complexes.

Methods: Synovial fibroblasts obtained from rheumatoid arthritis (RA) and osteoarthritis (OA) patients were stimulated with HMGB1 alone or in complex with LPS, IL-1 α or IL-1 β . Tumour necrosis factor (TNF) production was determined by enzyme-linked immunospot assay (ELISPOT) assessment. Levels of IL-10, IL-1 β , IL-6 and IL-8 were measured using Cytokine Bead Array and matrix metalloproteinase (MMP) 3 production was determined by ELISA.

Results: Stimulation with HMGB1 in complex with LPS, IL-1 α or IL-1 β enhanced production of TNF, IL-6 and IL-8. HMGB1 in complex with IL-1 β increased MMP production from both RASf and OASf. The cytokine production was inhibited by specific receptor blockade using detoxified LPS or IL-1 receptor antagonist, indicating that the synergistic effects were mediated through the partner ligand-reciprocal receptors TLR4 and IL-1RI, respectively.

Conclusions: HMGB1 in complex with LPS, IL-1 α or IL-1 β boosted proinflammatory cytokine- and MMP production in synovial fibroblasts from RA and OA patients. A mechanism for the pathogenic role of HMGB1 in arthritis could thus be through enhancement of inflammatory and destructive mechanisms induced by other proinflammatory mediators present in the arthritic joint.

Introduction

The highly conserved protein high mobility group box protein 1 (HMGB1) exerts vital functions in the nucleus of all eukaryotic cells. When tissue injury is inflicted and inflammation is induced, HMGB1 can be released extracellularly and can then convey inflammatory functions. Extracellular HMGB1 may induce cytokine production,

up-regulation of adhesion molecules on endothelial cells and activation of dendritic cells and T cells [1-11]. The reported presence of extracellular HMGB1 in multiple inflammatory conditions and the beneficial effects of HMGB1 blockade in preclinical models of inflammatory diseases have thus led to the acknowledgement of HMGB1 as an inflammatory mediator with pathogenic functions in several inflammatory diseases (reviewed in [12]).

HMGB1 interacts with the receptor for advanced glycosylated end products (RAGE), Toll-like receptor (TLR) 2

* Correspondence: Heidi.wahamaa@ki.se

¹Department of Women's and Children's Health, Pediatric Rheumatology Research Unit Karolinska Institutet, Astrid Lindgren Children Hospital/ Karolinska University Hospital, Stockholm, 17176, Sweden
Full list of author information is available at the end of the article

and with the TLR4 signalling complex. All three receptors are known to be involved in inflammatory processes and to possess the ability to activate NF κ B translocation. RAGE-HMGB1 interaction has mainly been studied regarding induction of cell migration while HMGB1 interaction with TLR2 and TLR4 mediates immune activation. We recently reported that HMGB1-induced cytokine production in macrophages is mediated via TLR4 and requires a reduced cysteine with a thiol group in amino acid position 106, supplementing the findings of Kazama *et al.* that HMGB1 released from apoptotic cells contains an oxidized cysteine in position 106 that induces tolerance rather than immune activation [13,14].

A second mechanism for the proinflammatory function of HMGB1 is due to the ability of HMGB1 to form complexes with inflammation-inducing agents such as LPS, IL-1 β , CpG-DNA (short single-stranded synthetic DNA molecules that contain a cytosine followed by a guanine) and the TLR2-ligand Pam₃CSK₄. Such complexes have been demonstrated to strongly enhance cytokine production in cell cultures. Additionally, in an experimental model of systemic lupus erythematosus HMGB1 was detected in circulating nucleosome complexes and the necessity of HMGB1 for these complexes to be immunogenic and to induce production of anti-DNA antibodies were demonstrated [15-20]. The molecular mechanism underlying the inflammatory activity of HMGB1 complexes and their ability to induce an enhanced response as compared to the partner molecule alone has not previously been addressed. Interestingly, it appears to be independent of the HMGB1 redox status as HMGB1, unable to induce cytokine production *per se*, still has the ability to induce such enhancement.

We and others have demonstrated an extracellular expression of HMGB1 in synovial tissue biopsies from rheumatoid arthritis (RA) patients and in joints from mice and rats with adjuvant-induced arthritis or collagen type II-induced arthritis [21-24]. Additionally, extranuclear HMGB1 localisation has been described in synovial tissue from osteoarthritis (OA) patients and in bovine osteoarthritic cartilage specimens [25,26]. Evidence for an active role of HMGB1 in arthritis pathogenesis is provided by studies demonstrating that a single injection of recombinant HMGB1 into knee joints of mice induces chronic synovitis [27] and, conversely, neutralisation of HMGB1 by treatment with antibodies or with a specific HMGB1 peptide antagonist significantly suppresses arthritis development in several studies [24,28-31].

Synovial fibroblasts (SFs) have been demonstrated to play a central role in arthritis pathogenesis, promoting both inflammation and bone and cartilage destruction [32,33]. SFs display an activated phenotype with up-regulated expression of multiple TLRs and interleukin 1 receptor type I (IL-1RI) [34-37].

We investigated whether the arthritogenic properties of HMGB1 could involve stimulation of SFs by HMGB1 complexes. We chose to study complexes formed by HMGB1 and endogenous mediators already described to be present in arthritic joints, that is, IL-1 α and IL-1 β , and with LPS which may also appear in arthritic joints [23,38-42]. We could demonstrate that SFs obtained from RA or OA patients responded to HMGB1 in complex with IL-1 α , IL-1 β or LPS, respectively, with enhanced production of tumor necrosis factor (TNF), IL-1, IL-6, IL-8 and MMP-3 and that the enhancement was mediated by interaction with IL-1RI or with TLR4, respectively. Knowing that uncomplexed HMGB1, depending on its redox status may or may not stimulate cytokine production, we initially tested the suitability of various HMGB1 batches for the present studies. We observed that every tested HMGB1 preparation, regardless of its inherent function to stimulate cytokine production, was capable to act in synergy in complexes with either LPS or IL-1 α or β . In order to facilitate the read-out of the HMGB1-complex experiments we thus chose to base our studies on HMGB1 batches that did not induce cytokine formation *per se*. These experiments have enabled us to propose a mechanism by which HMGB1 contributes to both inflammatory and destructive processes activated during arthritis.

Materials and methods

Cell cultures

Synovial fibroblasts obtained from nine RA and six OA patients were purchased from Asterand, (Detroit, MI, USA) or propagated from synovial tissues from RA and OA patients undergoing joint replacement surgery [43]. Briefly, synovial tissues were minced and explants were maintained in DMEM supplemented with 10% heat inactivated FCS (PAA Laboratories, Linz, Austria), 100 U/ml penicillin, 100 μ g/ml streptomycin and HEPES (Life Technologies, Paisley, Scotland, UK) (complete DMEM) in a tissue culture incubator at 37°C with 5% CO₂ content. After one to two weeks of culture the tissue specimens and non-adherent cells were discarded and cells were trypsinized with Trypsin-EDTA (Gibco, Scotland, UK) and subcultured by trypsination three to four weeks after initial explantation (at 80% confluence). All SF were used for experiments between passages 3 to 8. This study was approved by the Institutional Ethical Committee (Solna, Stockholm, Sweden; ethical number 2009/1262-31/3) and is in compliance with all ethical standards and patients' consent according to the Declaration of Helsinki.

Preparation of rHMGB1 from *E. coli*

Recombinant rat HMGB1 (rHMGB1) with a 99% identity to human HMGB1 [44] and containing a calmodulin-binding protein tag was expressed in *E. coli* strain BL21 (for sequence see ref [45]). Protein was purified by

sequential ion exchange chromatography (MonoS 5/50 GL column, GE Healthcare, Chalfont St. Giles, UK) and calmodulin affinity chromatography (Calmodulin sepharose 4B, GE Healthcare). Endotoxin was removed by filtration through Acodisc Units with Mustang E Membranes (0.25 μ m, Pall Life Sciences, East Hills, NY, USA), yielding endotoxin levels below 0.03 EU/ μ g protein as measured by the Limulus assay. Preparations of HMGB1 in 20 mM 3-(N-Morpholino) propanesulfonic acid (MOPS), 400 mM NaCl, 20 mM EGTA, 10 mM dithiothreitol at pH 8.0 were stored at -80°C until the day of use. The HMGB1 used in the studies could not induce cytokine production *per se*.

Immunocytochemistry; TLR4 and IL-1RI expression in synovial fibroblasts

Cells were cultured on 8-well culture slides, formaldehyde-fixed and subsequently stained for the presence of TLR4 and IL-1RI as previously described [30]. Briefly, slides were incubated with 2% fetal calf sera for 10 minutes and thereafter incubated overnight with anti-TLR4 antibody (sc-8694 Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) or monoclonal rabbit anti-IL-1RI (Epitomics, Burlingame, CA, USA). Subsequently, cells were incubated with Alexa Fluor[®] 594-conjugated anti-goat or rabbit antibodies (Molecular Probes, Invitrogen, Eugene, OR, USA) and counterstained with Hoechst 33342. PBS supplemented with 0.1% saponin was used in all steps of the staining procedure. In order to verify the staining specificity, parallel blocking experiments involving preabsorption of the specific primary antibody with blocking peptide or using a primary isotype-matched irrelevant IgG were performed.

Preparation of HMGB1-LPS, HMGB1-IL-1 α and HMGB1-IL-1 β complexes

HMGB1 diluted in PBS was incubated with IL-1 α , IL-1 β (R&D Systems, Minneapolis, MN, USA) or LPS (L-6529 Sigma, Saint Louis, MO, USA), respectively, in different ratios to give the indicated final concentrations in cell cultures. Solutions were incubated at 4°C for 16 h before addition to cell cultures. Formation of complexes has been previously demonstrated [17,18].

TNF Elispot assay

TNF Elispot assay (Enzyme-linked immunospot assay, R&D Systems, Minneapolis, MN, USA) was performed according to the manufacturer's instructions. Briefly, Multiscreen 96-well HTS Plate Clear (MSIPS4510, Millipore, Stockholm, Sweden) were pre-wetted with 35% ethanol, washed and coated with capture antibody (Gibco, Scotland, UK) overnight. After washing, plates were blocked with cell-specific medium for 2 h in a tissue culture incubator.

Synovial fibroblasts grown to confluence were trypsinized with Trypsin-EDTA and washed with complete DMEM. Cell viability was assessed using Trypan blue (Merck, Darmstadt, Germany) exclusion in every experimental set up and determined to be 95 to 100%.

Cells were plated at 4,000 cells/well and allowed to rest for 15 to 17 h in a tissue culture incubator at 37°C with 5% CO₂ content. Medium was discarded and cells were washed twice with OPTIMEM (Gibco, Scotland, UK) supplemented with 100 U/ml penicillin, 100 μ g/ml streptomycin and stimulated for 9 h in OPTIMEM with 4 μ g/ml or 100 ng/ml rHMGB1 alone or together (in complex or separately) with 1 to 100 ng/ml LPS or 0.05 to 0.5 ng/ml rIL-1 β as indicated. In some experiments, cells were pre-treated for 1 to 2 h with 0.5 to 5 μ g/ml IL-1RA, anakinra (Kineret; Amgen Europe, Breda, The Netherlands) or 10 μ g/ml detoxified LPS L-9023 (Sigma, Saint Louis, MO, USA). Following this stimulation plates were placed on ice for 15 minutes, washed with PBS/0.05% Tween 20 (PBS/Tw) and biotinylated TNF detection antibody was added. After overnight incubation plates were washed and incubated with Streptavidine-HRP (Mabtech AB, Stockholm, Sweden).

Spots were visualized following addition of tetramethylbenzidine (TMB) chromogen liquid substrate (Mabtech) and analyzed using an AID EliSpot Reader System, (AID, Strassberg, Germany).

Cytometric bead array (CBA) for detection of cytokine production

Cells were harvested as described for the TNF Elispot assay and 1 ml of 8×10^4 cells/ml in complete DMEM were plated in 12-well plates and rested for 15 to 17 h. Medium was discarded and cells were washed with OPTIMEM supplemented with 100 U/ml penicillin and 100 μ g/ml streptomycin and stimulated as indicated with 4 μ g/ml or 100 ng/ml rHMGB1 alone or in complex with 1 to 100 ng/ml LPS or 0.05 to 0.5 ng/ml, rIL-1 α or rIL-1 β , respectively. In some experiments cells were pre-treated for 1 to 2 h with 0.5 to 5 μ g/ml IL-1RA anakinra or 10 μ g/ml detoxified LPS L-9023. Supernatants were collected after 24 h of stimulation and stored at -20°C until analysis. Cell viability was assessed using Trypan blue (Merck, Darmstadt, Germany) exclusion in every experimental set up, at the beginning and at the end of every experiment and determined to be 95 to 100%.

Proinflammatory cytokine production was determined using flow CBA (B&D Biosciences, Pharmingen, San Diego, CA, USA) and analyzed according to the manufacturer's instructions.

ELISA assay for detection of MMP-3

Cells were cultured and stimulated as described above and supernatants collected after 24 h. The release of MMP-3 was analysed by ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instruction.

Statistical analysis

Kruskal-Wallis non-parametric ANOVA, Wilcoxon paired test or Mann Whitney were used to test statistical significance. All pair-wise comparisons were adjusted using Dunn's Multiple Comparisons Test. A *P*-value below 0.05 was considered to be statistically significant. The computer software program GraphPad Prism version 5 for Windows (GraphPad Software, San Diego, CA, USA) was used for all statistical tests.

Results

TLR4 and IL-1RI are expressed by synovial fibroblasts

TLR4 and IL-1RI, the reciprocal signalling receptors for the HMGB1 complex partner molecules LPS, IL-1 α and IL-1 β , were expressed on synovial fibroblasts from both RA (RASFs) and OA (OASFs) patients as demonstrated by immunofluorescent staining. A strong expression of both TLR4 and IL-1RI was recorded (Figure 1).

HMGB1 in complex with LPS increases the secretion of proinflammatory cytokines from synovial fibroblasts

Cultures of RASFs and OASFs were stimulated with HMGB1, LPS or complexes of HMGB1 and LPS, and the resultant cytokine production was analysed using Elispot and CBA. Stimulation with 4 μ g/ml HMGB1 did not induce TNF production in cultures of RASFs or OASFs. The selected doses, 1 to 100 ng/ml of LPS did not induce any or only minor TNF production above background levels. In contrast, significant TNF production occurred when RASF or OASF were stimulated with HMGB1 preincubated with 1 to 100 ng/ml LPS as compared to HMGB1 or LPS alone (Figure 2a). To define whether the enhancement of TNF production was an isolated effect or if HMGB1-LPS complex stimulation affected the production of additional cytokines we also analyzed the production of IL-10, IL-1 β , IL-6 and IL-8 using CBA. Similarly to the induced TNF production, HMGB1 in complex with LPS synergistically increased IL-6 and IL-8 production from both RASF and OASFs in a dose-dependent manner (Figure 2b). The synergistic effects of the complexes were statistically significant with a 5 to 15 and 10- to 20-fold increase in IL-6 and IL-8 production, respectively, as compared to 100 ng/ml LPS stimulation alone. Confirming the previously reported necessity of a preformed complex formation between HMGB1 and LPS, simultaneous addition of HMGB1 and LPS to cell cultures did not result in enhanced cytokine production (data not shown).

No induction of IL-10 or IL-1 β production could be detected after 24 h of stimulation with HMGB1 alone, LPS alone or HMGB1 in complex with LPS. As the cytokine response detected by Elispot or CBA did not differ significantly between RASFs and OASFs, median values of recorded data from these experiments are indicated with horizontal line in Figure 2a, b.

Thus, similarly to results previously demonstrated using human peripheral blood mononuclear cells (PBMCs) [18], RASFs and OASFs respond to HMGB1 in complex with LPS by an enhanced cytokine production. OK

HMGB1 in complex with IL-1 β increases proinflammatory cytokine secretion from synovial fibroblasts

Previous reports indicate that HMGB1 can interact with IL-1 β through formation of complexes with enhanced stimulatory capacity [17,18], which is of interest regarding arthritis pathogenesis as both IL-1 α and IL-1 β are abundant proinflammatory cytokines in the RA arthritic joint and they have also been detected in OA joints [38,39]. RASFs and OASFs responded to IL-1 β stimulation alone using a high IL-1 β dose of 0.5 ng/ml. In contrast, when using a physiologically more relevant IL-1 β dose of 0.05 ng/ml synovial fibroblasts did not produce cytokines. In accordance with the enhancing effects of HMGB1 in complex with LPS, preformed complexes of HMGB1 and the suboptimal dose of IL-1 β induced a significant production of TNF (Figure 3a), and also of IL-6 and IL-8 (Figure 3b). The IL-6 production was increased 30- to 180-fold and IL-8 production by 100- to > 400-fold when stimulated with HMGB1-IL-1 β complexes compared to stimulation with the suboptimal IL-1 β concentration alone. No effect on the production of IL-10 or IL-1 β could be detected when complexes were applied. Compared to the HMGB1-LPS complex experiments, the dose of HMGB1 used was much lower, 100 ng/ml, in this experimental setting, demonstrating that low, cytokine-like levels of HMGB1 display a potentiating effect on cytokine production. As the cytokine response detected by Elispot or CBA did not differ significantly between RASFs and OASFs, median values of pooled recorded data from these experiments are indicated with horizontal line in Figure 2a, b.

HMGB1-IL-1 β complex stimulation induced higher cytokine levels than HMGB1-LPS complex stimulation and, correspondingly, high dose IL-1 β alone was more potent in inducing cytokine production than was high dose LPS alone (Figures 2a, b and 3a, b). Furthermore, simultaneous addition of both HMGB1 and the suboptimal dose of IL-1 β (without complex formation) to cell cultures did not raise cytokine production above background levels (data not shown), underlining the importance of complex formation between HMGB1 and IL-1 β .

Enhanced MMP-3 production following stimulation with complexes of HMGB1 and IL-1 β

Destructive features of arthritis are partly due to the production of MMPs with the ability to degrade extracellular matrix and cartilage. We investigated whether production of MMP-3, a cartilage-degrading MMP,




Figure 1 TLR4 and IL-1RI are expressed on synovial fibroblasts. Synovial fibroblasts were cultured in chamber slides without exogenous stimulation. TLR4 and IL-1RI expression was determined by immunocytochemical staining (red Alexa Fluor[®] 594) and nuclei were counterstained with Hoechst (blue). **A)** TLR4 staining, **B)** IL-1RI staining, **C)** staining with TLR4 specific antibody pre-incubated with blocking peptide, **D)** control staining with irrelevant rabbit IgG.


could be enhanced in RASFs and OASFs by stimulation with HMGB1-IL-1 β complexes.

Both RASFs and OASFs spontaneously released MMP-3. Despite the differences in spontaneous MMP-3 production all but one cell line responded with significantly enhanced MMP-3 production following stimulation with HMGB1 in complex with IL-1 β (Figure 3c). Enhanced MMP-3 production was observed in the non-responding cell line when stimulated with HMGB1 in complex with a higher dose of IL-1 β (0.5 ng/ml), data not included in

Figure 3c. This could suggest that the enhancing potential of HMGB1 in complex with IL-1 β is dependent on the response to IL-1 β as the ligand.

HMGB1-LPS complexes utilise TLR4 signalling for induction of cytokine production

In order to elucidate the receptor dependence of the cytokine-enhancing effects of the investigated HMGB1-ligand complexes we investigated TLR4 requirement for HMGB1-LPS mediated cytokine production. RASFs and



OASFs were incubated with detoxified LPS (LPS with the fatty acid moieties of the lipid A portion removed, resulting in a TLR4-binding LPS with 10,000-fold lower toxicity than regular LPS) for 1 to 2 h followed by stimulation with HMGB1 in complex with LPS.

Detoxified LPS inhibited HMGB1-LPS complex-mediated IL-6 and IL-8 production from RASFs and OASFs (Figure 4), thus demonstrating a TLR4 dependency for the cytokine-inducing signalling events induced by HMGB1 in complex with LPS. Similarly, pre-incubation with detoxified LPS inhibited the low cytokine production induced by stimulation with LPS alone (Figure 4).

HMGB1-IL-1 α and HMGB1-IL-1 β complexes utilise IL-1RI signalling for induction of cytokine production

Similar to complexes of HMGB1-IL-1 β , complexes of HMGB1 with IL-1 α stimulated RASFs and OASFs to significantly increased production of IL-8 and IL-6 determined by CBA, as compared to IL-1 α alone (Figure 5a).

In order to investigate the role of the signalling IL-1 receptor, IL-1RI, for the observed cytokine production induced by HMGB1 in complex with IL-1 α or IL-1 β we utilised IL-1RA, Anakinra. RASFs and OASFs were incubated with IL-1RA for 1 h prior to stimulation with HMGB1, IL-1 α , IL-1 β and HMGB1 in complex with either IL-1 α or IL-1 β . IL-1RA significantly inhibited HMGB1-IL-1 α complex mediated IL-6 and IL-8 production from RASFs and OASFs (Figure 5a) and HMGB1-IL-1 β complex-mediated TNF (Figure 5b), IL-6 and IL-8


(Figure 5c) production from RASFs and OASFs. Our results indicate that IL-1RI serves as a signalling receptor for HMGB1-IL-1 α - and HMGB1-IL-1 β complex-mediated cytokine production.

HMGB1-IL-1 β -complexes do not utilise TLR4 signalling for induction of cytokine production

HMGB1 has been demonstrated to interact with TLR4 and thereby to induce cytokine production [13,46]. Although the HMGB1 used in this study did not express any cytokine-inducing ability *per se*, we wanted to ascertain that the enhancing effects of the HMGB1-IL-1 β complex were not due to an interaction of HMGB1 with TLR4. RASFs and OASFs were incubated with detoxified LPS 1 to 2 h prior to stimulation with HMGB1 alone or HMGB1-IL-1 β -complexes and cytokine production was recorded. No significant reduction of the HMGB1-IL-1 β complex-induced IL-6 and IL-8 production could be recorded as a consequence of pre-treatment with detoxified LPS (Figure 6). Our results thus demonstrate that the cytokine-enhancing ability of HMGB1-IL-1 β complexes is dependent on IL-1RI signalling but not on TLR4 signalling.

Discussion


Herein we reveal a mechanism by which HMGB1 may contribute to both inflammatory and destructive processes present during arthritis. Synovial fibroblasts stimulated with HMGB1 in complex with IL-1 α , IL-1 β or LPS



increased their cytokine production. Additionally, HMGB1-IL-1β complexes also increased MMP-3 production. Previous studies have demonstrated that HMGB1 is released from activated immune cells and from stressed synoviocytes in arthritic joints and that blockade of extracellular HMGB1 suppresses disease progression in experimental models. Here we demonstrate that HMGB1 potentiates the effects of two endogenous molecules reported to be present in arthritic joints, namely IL-1α/IL-1β and the microbial mediator LPS. The enhancing effects are caused by complex formation between HMGB1 and the partner molecules. Such immunostimulatory features of HMGB1 in complex with IL-1β and LPS have previously been reported by us and

others, while the synergistic effects of HMGB1 and IL-1α are described for the first time in this study.

So, in addition to the direct cytokine-inducing effects of HMGB1 previously reported, our results suggest that the arthritogenic features of HMGB1 can also be mediated by the enhanced activity of molecules in complex with HMGB1. HMGB1 that is actively secreted by activated macrophages or passively released from necrotic cells signals via TLR4 since the TLR4-binding epitope of the HMGB1 molecule expresses its cysteine in position 106 (C106) in reduced form, which is a prerequisite for activation of this signal pathway [47,13]. The C106 may then later be oxidized in the inflammatory milieu and will lose its capacity to signal via the TLR4 complex. However,




this pacified version of HMGB1 may still act as a proinflammatory molecule if the environment contains danger molecules like IL-1 α , IL-1 β or LPS. HMGB1 will then act as an extracellular sensor and form complexes with these molecules that will enhance subsequent cytokine production in fibroblasts and other cells.

The ligands for complex formation with HMGB1 in this study, IL-1 α , IL-1 β and LPS, were chosen for three reasons; *I*) we and others have previously demonstrated a cytokine-enhancing effect of such complexes in macrophages [16,17,48]; *II*) HMGB1 [23], LPS [42], IL-1 α and IL-1 β [38-40] have all been detected in RA and OA synovial samples; and *III*) fibroblasts are pivotal cells in arthritic inflammation that express the suggested receptors for HMGB1 [23,35,49-51] in addition to the LPS receptor TLR4 and IL-1RI [34-37].

Complexes of HMGB1 with IL-1 α , IL-1 β or LPS each strongly enhanced the production of TNF, IL-6 and IL-8,

while the production of both IL-10 and IL-1 β was not affected. It is of interest to note that fibroblasts retrieved from both OA and RA patients shared a similar ability to respond to HMGB1-complex stimulation. Previous studies have reported a difference in extracellular HMGB1 levels in RA and OA synovial fluid with HMGB1 levels being significantly higher (54.1 \pm SD 73.0 ng/ml) in RA synovial fluid than in OA synovial fluid (12.0 \pm SD 17.7 ng/ml [23]). Similarly, the IL-1 β levels recorded in synovial fluid levels from RA patients are roughly 10 times higher than those recorded in OA patients [39]. One can thus assume that HMGB1-IL-1 β complexes are more likely formed *in vivo* during RA than during OA. This could affect the activation status of synovial fibroblasts contributing to a more inflammatory and destructive disease course in RA than in OA.

The amounts of HMGB1 and IL-1 β used in our study correspond to levels recorded in RA synovial fluid;




ranging from 10 to 300 ng/ml and 5 to 193 pg/ml, respectively [23,40,52]. A study by Garcia-Arnandis *et al.* [25] demonstrated that simultaneous addition of HMGB1 and IL-1 β induced enhanced IL-6 and IL-8 production in OA synovial fibroblast cultures, which we did not observe in our study. However, the IL-1 β concentration used in their experiments was 20-fold higher than in our experimental setup, and also higher than levels recorded in RA synovial fluid. It is plausible that the high IL-1 β levels used could lead to HMGB1-IL-1 β complex formation during the cell stimulation and thus their findings are in agreement with our results.

LPS, as well as other constituents of various pathogens, have been reported to be present in arthritic joints

[41,42]. This has led to the hypothesis that infections can be both a cause of arthritis onset and also of disease exacerbation. However, no infectious agent in particular has been pinpointed to be associated with chronic arthritis. The data presented in this paper together with earlier studies on the interaction of HMGB1 with different TLR-ligands suggest that HMGB1 might be a unifying factor for the contribution of various infections to arthritis pathogenesis.

Our data clearly demonstrate the striking ability of HMGB1 complexes to enhance both cytokine production and MMP-3 production by SFs when compared to equivalent doses of the ligand molecules alone. We had originally hypothesized that the enhancing effects would



be mediated by simultaneous engagement of an HMGB1 receptor (RAGE or TLR4) and the partner ligand receptor. By blocking IL-1RI and TLR4 with the respective receptor antagonists (IL-1 receptor antagonist or detoxified LPS) we could demonstrate that the stimulatory activities of the HMGB1-IL-1α and IL-1β complexes were mediated via the IL-1RI and that the stimulatory activity of the HMGB1-LPS complex was mediated via TLR4. Interestingly, blockade of TLR4 did not suppress the stimulation induced by HMGB1-IL-1β complexes, thus ruling out that the synergistic effects were mediated by a simultaneous interaction of TLR4 and IL-1RI. This conclusion is also supported by the fact that the HMGB1 used in our studies did not alone possess an endogenous cytokine-inducing capacity, this otherwise being mediated through TLR4 interaction [13,46]. Attempts to block RAGE, the most studied receptor for HMGB1, using a receptor antagonist failed as we could not define a functional antagonist. Results from studies when soluble RAGE (sRAGE) was added to the cell culture (data not included) demonstrated that sRAGE could suppress the activity of the HMGB1 complexes. However, this only confirms that HMGB1 can bind to RAGE; the

suppressive effects were most likely caused by steric hindrance rather than by an inactivation of RAGE signalling. Data from our laboratory (H. Hreggvidsdottir *et al.*, submitted manuscript) indicate that RAGE is not involved in HMGB1 complex signaling as macrophages from RAGE-deficient mice respond equally well to HMGB1 complex stimulation as from wild type mice. However, a remaining possibility for the mechanism of HMGB1 complex-induced enhancement could be the involvement of an as yet undefined HMGB1 receptor in a receptor-pair with the partner ligand receptor. A second possibility could be a multiaggregation of ligand receptors caused by the HMGB1-ligand complex leading to enhanced activity. Both scenarios deserve further investigations.

Conclusions

Preformed complexes of HMGB1 with IL-1α, IL-1β or LPS have the ability to strongly enhance production of both proinflammatory mediators and of tissue destructive enzyme by synovial fibroblasts derived from RA and OA patients. HMGB1 thus acts as an endogenous amplifier endowed with a capacity to magnify responses to trace amounts of endogenous and exogenous danger signals.

This effect is mediated via the reciprocal ligand receptors, IL-1RI and TLR4, for the ligands complexed to HMGB1 investigated in this study. HMGB1 without direct cytokine-inducing effects on its own might be present in arthritic joints as HMGB1 is released by apoptotic cells. Furthermore, exposure of cytokine-inducing, reduced HMGB1 to an oxidative burst during inflammation may downregulate its direct proinflammatory features by changing its redox status. We demonstrate that non-cytokine-inducing HMGB1 can form strongly inflammation-enhancing complexes with inflammatory mediators present in arthritic joints. These HMGB1 complexes act on both synovial fibroblasts and on monocytes and enhance their activation status. Thus in addition to the direct cytokine-inducing effect of HMGB1 previously described, we, herein, demonstrate a second mechanism by which HMGB1 may contribute to the arthritogenic process.

Through this study we have increased knowledge of the proinflammatory functions of HMGB1 in arthritis in both RA and OA settings. We have demonstrated enhancing effects of HMGB1 on both inflammatory and destructive disease mechanisms and further consolidated HMGB1 as a putative target for successful therapy.

Abbreviations

CpG-DNA: short single-stranded synthetic DNA molecules that contain a cytosine followed by a guanine; ELISPOT: enzyme-linked immunospot assay; HMGB1: high mobility group box protein 1; IL-1 α : interleukin 1 alpha; IL-1 β : interleukin 1 beta; IL-1RI: interleukin 1 receptor type 1; IL-1RA: interleukin 1 receptor antagonist; LPS: lipopolysaccharide; MMP-3: matrix metalloproteinase 3; OA: osteoarthritis; OASF: osteoarthritis synovial fibroblasts; PBMCs: peripheral blood mononuclear cells; RA: rheumatoid arthritis; RAGE: receptor for advanced glycation end products; RASF: rheumatoid arthritis synovial fibroblasts; TMB: tetramethylbenzidine; TNF: tumour necrosis factor; TLR: Toll-like receptor.

Acknowledgements

We thank Emelie Lundström and Omri Snir for their help with the statistical analysis, Lars Ottosson for help with the images, Sara Waheddoost for experimental assistance and Dr RA Harris for linguistic advice. This study was supported by the regional agreement on medical training and clinical research (ALF) between the Stockholm County Council and Karolinska Institutet, Åke Wiberg Foundation, Stiftelsen Allmänna Barnhuset, the Freemason Lodge Barnhuset in Stockholm, the Swedish Association against Rheumatism von Kantzow foundation, Swedish Medical Research Council, Loo and Hans Ostermans Foundation, Axel and Eva Wallströms Foundation and the King Gustaf V's Foundation.

Author details

¹Department of Women's and Children's Health, Pediatric Rheumatology Research Unit Karolinska Institutet, Astrid Lindgren Children Hospital/Karolinska University Hospital, Stockholm, 17176, Sweden. ²Department of Medicine, Rheumatology Research Unit Karolinska Institutet, CMM Karolinska University Hospital, Stockholm, 17176, Sweden.

Authors' contributions

HW was responsible for the study design, experimental work, data collection and the manuscript preparation. HS participated in study design, experimental work and statistical analysis and in manuscript preparation. HH participated in study design, experimental work and in manuscript preparation. KP performed the immunocytochemical stainings and ACA

participated in cell culture work and with technical support during many experiments. UA was responsible for study design, supervision and manuscript preparation. HEH was responsible for study design, supervision and she drafted the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 16 February 2011 Revised: 21 June 2011

Accepted: 26 August 2011 Published: 26 August 2011

References

1. Yang H, Wang H, Tracey KJ: HMG-1 rediscovered as a cytokine. *Shock* 2001, **15**:247-253.
2. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. *J Exp Med* 2000, **192**:565-570.
3. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature* 2002, **418**:191-195.
4. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. *Blood* 2003, **101**:2652-2660.
5. Treutiger CJ, Mullins GE, Johansson AS, Rouhainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE: High mobility group 1 B-box mediates activation of human endothelium. *J Intern Med* 2003, **254**:375-385.
6. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ: High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. *J Leukoc Biol* 2007, **81**:59-66.
7. Rovere-Querini P, Capobianco A, Scaffidi P, Valentini B, Catalanotti F, Giazzon M, Dumitriu IE, Müller S, Iannaccone M, Traversari C, Bianchi ME, Manfredi AA: HMGB1 is an endogenous immune adjuvant released by necrotic cells. *EMBO Rep* 2004, **5**:825-830.
8. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ, Chiorazzi N: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. *J Immunol* 2004, **173**:307-313.
9. Dumitriu IE, Baruah P, Valentini B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, Rovere-Querini P: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. *J Immunol* 2005, **174**:7506-7515.
10. Locher C, Rusakiewicz S, Tesnière A, Ghiringhelli F, Apetoh L, Kroemer G, Zitvogel L: Witch hunt against tumor cells enhanced by dendritic cells. *Ann N Y Acad Sci* 2009, **1174**:51-60.
11. Sundberg E, Fasth AE, Palmblad K, Harris HE, Andersson U: High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. *Immunobiology* 2009, **214**:303-309.
12. Andersson U, Tracey KJ: HMGB1 is a therapeutic target for sterile inflammation and infection. *Annu Rev Immunol* 2011, **29**:139-162.
13. Yang H, Hreggvidsdóttir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ: A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. *Proc Natl Acad Sci USA* 2010, **107**:11942-11947.
14. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA: Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. *Immunity* 2008, **29**:21-32.
15. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, Sitia G, Yap GS, Wan Y, Biron CA, Bianchi ME, Wang H, Chu WM: A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. *Blood* 2007, **110**:1970-1981.
16. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Nawroth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. *Nat Immunol* 2007, **8**:487-496.

17. Sha Y, Zmijewski J, Xu Z, Abraham E: **HMGB1 develops enhanced proinflammatory activity by binding to cytokines.** *J Immunol* 2008, **180**:2531-2537.
18. Hreggvidsdottir HS, Ostberg T, Wähämaa H, Schierbeck H, Aveberger AC, Klevenvall L, Palmblad K, Ottosson L, Andersson U, Harris HE: **The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation.** *J Leukoc Biol* 2009, **86**:655-662.
19. Urbanovicute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE: **Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE.** *J Exp Med* 2008, **205**:3007-3018.
20. Kwak MS, Wu J, Kim ES, Ji Y, Min HJ, Yoo JH, Choi JE, Cho HS, Shin JS: **Identification of lipopolysaccharide-binding peptide regions within HMGB1 and their effects on subclinical endotoxemia in a mouse model.** *Eur J Immunol* 2011.
21. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, Ulloa L, Yang H, Yan XJ, Furie R, Chiorazzi N, Tracey KJ, Andersson U, Harris HE: **High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis.** *Arthritis Rheum* 2002, **46**:2598-2603.
22. Palmblad K, Sundberg E, Diez M, Söderling R, Aveberger AC, Andersson U, Harris HE: **Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis.** *Arthritis Res Ther* 2007, **9**:R35.
23. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I: **High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine.** *Arthritis Rheum* 2003, **48**:971-981.
24. Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T, Yamada S, Nagayama S, Hashiguchi K, Sunahara N, Fukuzaki K, Nagata R, Komiya S, Maruyama I, Fukuda T, Abeyama K: **Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis.** *Arthritis Rheum* 2008, **58**:2675-2685.
25. Garcia-Arnandis I, Guillén MI, Gomar F, Pelletier JP, Martel-Pelletier J, Alcaraz MJ: **High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1beta in osteoarthritic synoviocytes.** *Arthritis Res Ther* 2010, **12**:R165.
26. Heinola T, Kouri VP, Clarijs P, Ciferska H, Sukura A, Salo J, Kontinen YT: **High mobility group box-1 (HMGB-1) in osteoarthritic cartilage.** *Clin Exp Rheumatol* 2010, **28**:511-518.
27. Pullerits R, Jonsson IM, Verdrengh M, Bokarewa M, Andersson U, Erlandsson-Harris H, Tarkowski A: **High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis.** *Arthritis Rheum* 2003, **48**:1693-1700.
28. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE: **Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity.** *Arthritis Rheum* 2003, **48**:2052-2058.
29. Pisetsky DS, Erlandsson-Harris H, Andersson U: **High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease.** *Arthritis Res Ther* 2008, **10**:209.
30. Ostberg T, Kohki Kawane, Shigekazu Nagata, Huan Yang, Sangeeta Chavan, Lena Klevenvall, Marco Bianchi, Helena Erlandsson Harris, Ulf Andersson, Karin Palmblad: **Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model.** *Arthritis Rheum* 2010, **62**:2963-2972.
31. Schierbeck H, Lundbäck P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U, Ottosson L: **Monoclonal anti-HMGB1 antibody protection in two experimental arthritis models.** *Mol Med* 2011.
32. Mor A, Abramson SB, Pillinger MH: **The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction.** *Clin Immunol* 2005, **115**:118-128.
33. Pap T, Müller-Ladner U, Gay RE, Gay S: **Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis.** *Arthritis Res* 2000, **2**:361-367.
34. Brentano F, Kyburz D, Schorr O, Gay R, Gay S: **The role of Toll-like receptor signalling in the pathogenesis of arthritis.** *Cell Immunol* 2005, **233**:90-96.
35. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, Gay RE, Gay S, Kyburz D: **Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis.** *Arthritis Rheum* 2008, **58**:3684-3692.
36. Jung YO, Cho ML, Kang CM, Jhun JY, Park JS, Oh HJ, Min JK, Park SH, Kim HY: **Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts.** *Immunol Lett* 2007, **109**:21-27.
37. Kay J, Calabrese L: **The role of interleukin-1 in the pathogenesis of rheumatoid arthritis.** *Rheumatology (Oxford)* 2004, **43**:iii2-iii9.
38. Farahat MN, Yanni G, Poston R, Panayi GS: **Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis.** *Ann Rheum Dis* 1993, **52**:870-875.
39. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M: **Synovial membrane inflammation and cytokine production in patients with early osteoarthritis.** *J Rheumatol* 1997, **24**:365-371.
40. Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, Pawelec G: **Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue.** *Ann Rheum Dis* 1992, **51**:731-734.
41. Melief MJ, Hoijer MA, Van Paassen HC, Hazenberg MP: **Presence of bacterial flora-derived antigen in synovial tissue macrophages and dendritic cells.** *Br J Rheumatol* 1995, **34**:1112-1116.
42. Kempell KE, Cox CJ, Hurle M, Wong A, Wilkie S, Zanders ED, Gaston JS, Crowe JS: **Reverse transcriptase-PCR analysis of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue.** *Infect Immun* 2000, **68**:6012-6026.
43. Glennäs A, Thorsrud AK, Rugstad HE, Jellum E: **Mapping of proteins from cultured fibroblasts of synovial and subcutaneous origin by high resolution two-dimensional polyacrylamide gel electrophoresis.** *Ann Rheum Dis* 1985, **44**:302-306.
44. Paonessa G, Frank R, Cortese R: **Nucleotide sequence of rat liver HMGI cDNA.** *Nucleic Acids Res* 1987, **15**:9077.
45. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: **HMGI as a late mediator of endotoxin lethality in mice.** *Science* 1999, **285**:248-251.
46. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H: **HMGB1 signals through toll-like receptor (TLR) 4 and TLR2.** *Shock* 2006, **26**:174-179.
47. Antoine DJ, Williams DP, Kipar A, Laverty H, Park BK: **Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity.** *Mol Med* 2010, **16**:479-490.
48. Youn JH, Oh YJ, Kim ES, Choi JE, Shin J: **High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes.** *J Immunol* 2008, **180**:5067-5074.
49. Kim KW, Cho ML, Lee SH, Oh HJ, Kang CM, Ju JH, Min SY, Cho YG, Park SH, Kim H: **Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation.** *Immunol Lett* 2007, **110**:54-64.
50. Hou FF, Jiang JP, Guo JQ, Wang GB, Zhang X, Stern DM, Schmidt AM, Owen WF Jr: **Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis.** *J Am Soc Nephrol* 2002, **13**:1296-1306.
51. Steenvoorden MM, Toes RE, Ronda HK, Huizinga TW, Degroot J: **RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro.** *Clin Exp Rheumatol* 2007, **25**:740-742.
52. Rchette P, François M, Vicaud E, Fitting C, Bardin T, Corvol M, Savouret JF, Rannou F: **A high interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis.** *J Rheumatol* 2008, **35**:1650-1654.

doi:10.1186/ar3450

Cite this article as: Wähämaa et al.: High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. *Arthritis Research & Therapy* 2011 **13**:R136.